TAP2_HUMAN - PTM Information in dbPTM

Basic Information of Protein

• UniProt ID: TAP2_HUMAN
• UniProt AC: Q03519
• Protein Name: Antigen peptide transporter 2
• Gene Name: TAP2
• Organism: Homo sapiens (Human).
• Sequence Length: 686
• Subcellular Localization: Endoplasmic reticulum membrane; Multi-pass membrane protein. The transmembrane segments seem to form a pore in the membrane.
• Protein Description: Involved in the transport of antigens from the cytoplasm to the endoplasmic reticulum for association with MHC class I molecules. Also acts as a molecular scaffold for the final stage of MHC class I folding, namely the binding of peptide. Nascent MHC class I molecules associate with TAP via tapasin. Inhibited by the covalent attachment of herpes simplex virus ICP47 protein, which blocks the peptide-binding site of TAP. Inhibited by human cytomegalovirus US6 glycoprotein, which binds to the lumenal side of the TAP complex and inhibits peptide translocation by specifically blocking ATP-binding to TAP1 and prevents the conformational rearrangement of TAP induced by peptide binding. Inhibited by human adenovirus E3-19K glycoprotein, which binds the TAP complex and acts as a tapasin inhibitor, preventing MHC class I/TAP association..
• Protein Sequence: MRLPDLRPWTSLLLVDAALLWLLQGPLGTLLPQGLPGLWLEGTLRLGGLWGLLKLRGLLGFVGTLLLPLCLATPLTVSLRALVAGASRAPPARVASAPWSWLLVGYGAAGLSWSLWAVLSPPGAQEKEQDQVNNKVLMWRLLKLSRPDLPLLVAAFFFLVLAVLGETLIPHYSGRVIDILGGDFDPHAFASAIFFMCLFSFGSSLSAGCRGGCFTYTMSRINLRIREQLFSSLLRQDLGFFQETKTGELNSRLSSDTTLMSNWLPLNANVLLRSLVKVVGLYGFMLSISPRLTLLSLLHMPFTIAAEKVYNTRHQEVLREIQDAVARAGQVVREAVGGLQTVRSFGAEEHEVCRYKEALEQCRQLYWRRDLERALYLLVRRVLHLGVQMLMLSCGLQQMQDGELTQGSLLSFMIYQESVGSYVQTLVYIYGDMLSNVGAAEKVFSYMDRQPNLPSPGTLAPTTLQGVVKFQDVSFAYPNRPDRPVLKGLTFTLRPGEVTALVGPNGSGKSTVAALLQNLYQPTGGQVLLDEKPISQYEHCYLHSQVVSVGQEPVLFSGSVRNNIAYGLQSCEDDKVMAAAQAAHADDFIQEMEHGIYTDVGEKGSQLAAGQKQRLAIARALVRDPRVLILDEATSALDVQCEQALQDWNSRGDRTVLVIAHRLQTVQRAHQILVLQEGKLQKLAQL

Overview of Protein Modification Sites with Functional and Structural Information

Experimental Post-Translational Modification Sites

* ASA = Accessible Surface Area

Locations	Modification	Substrate Peptides & Secondary Structure	ASA (%)	Reference
54	Ubiquitination	GGLWGLLKLRGLLGF CHHHHHHHHHHHHHH	40.98	21906983
135	Ubiquitination	EQDQVNNKVLMWRLL HHHHHHHHHHHHHHH	31.38	21890473
135	Ubiquitination	EQDQVNNKVLMWRLL HHHHHHHHHHHHHHH	31.38	21890473
135	Ubiquitination	EQDQVNNKVLMWRLL HHHHHHHHHHHHHHH	31.38	21890473
135	Ubiquitination	EQDQVNNKVLMWRLL HHHHHHHHHHHHHHH	31.38	21890473
135	Ubiquitination	EQDQVNNKVLMWRLL HHHHHHHHHHHHHHH	31.38	21890473
216	Phosphorylation	CRGGCFTYTMSRINL CCCCCCHHHHHHHHH	4.72	24719451
217	Phosphorylation	RGGCFTYTMSRINLR CCCCCHHHHHHHHHH	12.95	24719451
219	Phosphorylation	GCFTYTMSRINLRIR CCCHHHHHHHHHHHH	23.39	24719451
232	Phosphorylation	IREQLFSSLLRQDLG HHHHHHHHHHHHHCC	24.88	24719451
245	Ubiquitination	LGFFQETKTGELNSR CCCCCCCCCCCCCCC	54.50	21890473
245	Ubiquitination	LGFFQETKTGELNSR CCCCCCCCCCCCCCC	54.50	21890473
245	Ubiquitination	LGFFQETKTGELNSR CCCCCCCCCCCCCCC	54.50	21890473
245 (in isoform 2)	Ubiquitination	-	54.50	-
245	Ubiquitination	LGFFQETKTGELNSR CCCCCCCCCCCCCCC	54.50	21890473
245	Ubiquitination	LGFFQETKTGELNSR CCCCCCCCCCCCCCC	54.50	21906983
282	Phosphorylation	LVKVVGLYGFMLSIS HHHHHHHHHHHHCCC	11.46	22210691
287	Phosphorylation	GLYGFMLSISPRLTL HHHHHHHCCCHHHHH	14.83	26074081
289	Phosphorylation	YGFMLSISPRLTLLS HHHHHCCCHHHHHHH	10.69	26074081
293	Phosphorylation	LSISPRLTLLSLLHM HCCCHHHHHHHHHCC	27.25	26074081
296	Phosphorylation	SPRLTLLSLLHMPFT CHHHHHHHHHCCCHH	31.81	26074081
308	Ubiquitination	PFTIAAEKVYNTRHQ CHHHHHHHHHCHHHH	45.34	-
356	Ubiquitination	EHEVCRYKEALEQCR HHHHHHHHHHHHHHH	19.70	21890473
356	2-Hydroxyisobutyrylation	EHEVCRYKEALEQCR HHHHHHHHHHHHHHH	19.70	-
455	Phosphorylation	DRQPNLPSPGTLAPT CCCCCCCCCCCCCCC	38.84	26657352
458	Phosphorylation	PNLPSPGTLAPTTLQ CCCCCCCCCCCCEEE	24.11	26657352
469	Ubiquitination	TTLQGVVKFQDVSFA CEEECEEEEEEEEEE	34.60	-
492	Phosphorylation	VLKGLTFTLRPGEVT EEEECEEEECCCEEE	19.34	24719451
597	Phosphorylation	QEMEHGIYTDVGEKG HHHHCCCCCCCCHHH	11.07	28796482
598	Phosphorylation	EMEHGIYTDVGEKGS HHHCCCCCCCCHHHC	23.45	28796482
603 (in isoform 2)	Ubiquitination	-	58.91	-
603	Ubiquitination	IYTDVGEKGSQLAAG CCCCCCHHHCCCCHH	58.91	21906983
612	2-Hydroxyisobutyrylation	SQLAAGQKQRLAIAR CCCCHHHHHHHHHHH	36.15	-
612 (in isoform 2)	Ubiquitination	-	36.15	-
612	Ubiquitination	SQLAAGQKQRLAIAR CCCCHHHHHHHHHHH	36.15	21906983
679	Ubiquitination	ILVLQEGKLQKLAQL HHHCCCCHHHHHHCC	47.17	21890473
682	Ubiquitination	LQEGKLQKLAQL--- CCCCHHHHHHCC---	57.11	21890473
682	Ubiquitination	LQEGKLQKLAQL--- CCCCHHHHHHCC---	57.11	21890473
682	Ubiquitination	LQEGKLQKLAQL--- CCCCHHHHHHCC---	57.11	21890473
682	Ubiquitination	LQEGKLQKLAQL--- CCCCHHHHHHCC---	57.11	-
693	Phosphorylation	L-------------- C--------------		-

Upstream regulatory proteins (kinases for phosphorylation sites, E3 ubiquitin ligases of ubiquitination sites, ...)

Oops, there are no upstream regulatory protein records of TAP2_HUMAN !!

Functions of PTM Sites

Oops, there are no descriptions of PTM sites of TAP2_HUMAN !!

Disease-associated PTM Sites based on SAP

* Distance = the distance between SAP position and PTM sites.

Oops, there are no SNP-PTM records of TAP2_HUMAN !!

Protein-Protein Interaction

Interacting Protein	Gene Name	Interaction Type	PPI Reference
HLAG_HUMAN	HLA-G	physical	9103419
1C07_HUMAN	HLA-C	physical	9551969
A4_HUMAN	APP	physical	21832049
B2MG_HUMAN	B2M	physical	8805302
1A02_HUMAN	HLA-A	physical	8805302
1A03_HUMAN	HLA-A	physical	8805302
1A01_HUMAN	HLA-A	physical	8805302
1A26_HUMAN	HLA-A	physical	8805302
HLAE_HUMAN	HLA-E	physical	9427624
TAP1_HUMAN	TAP1	physical	28514442

Drug and Disease Associations

• Kegg Disease
• H00093: Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndro
• H00984: Bare lymphocyte syndrome (BLS) type1
• OMIM Disease
• 604571: Bare lymphocyte syndrome 1 (BLS1)
• Kegg Drug
• There are no disease associations of PTM sites.
• DrugBank
• There are no disease associations of PTM sites.